secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-10-18T23:59:59+00:00
Accession:  0001628280-22-026572
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics announces $250M public offering of common stock
-------------------------------------------------------------------

- Denali to sell $250M of common stock; underwriters have 30-day option for additional 15%.
- Goldman Sachs, J.P. Morgan, and Jefferies act as joint book-running managers for the offering.
- Preliminary cash, cash equivalents, and marketable securities estimated at $1.11B as of Sep 30, 2022.
- Company has no approved products and expects to continue incurring significant net losses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000162828022026572/0001628280-22-026572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000162828022026572/dnli-20221018.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-026572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer